: Scanning electron microscope (SEM) image of a microcontainer made of SU-8.
There are two crucial steps for successful delivery of orally administered drugs; drug dissolution and drug absorption (Avdeef and Tsinman, 2008) . Early prediction of the intestinal absorption of a compound is essential for further development, making the ability of in vitro methods to provide this information extremely important. Cell culture models are one of many methods used to study intestinal absorption (Patel et al., 2006; Pretorius and Bouic, 2009 ). The Caco-2 cell line is an epithelial cell line originating from a human colonic adenocarcinoma, which represents many of the characteristics and functions found in the epithelium of the small intestine (tight junctions, microvilli, growth factor receptors, and major drug metabolizing enzymes) (Berginc et al., 2012; Hidalgo et al., 1989; Hilgers et al., 1990) . The Caco-2 cell model has become a useful in vitro tool to predict permeability and absorption of drugs across the small intestinal membrane, and is a valuable set-up to be employed during the development of oral drug delivery systems (Hidalgo et al., 1989) . Even though, Caco-2 cells can be a good in vitro model for permeation, it lacks the mucus layer, covering the epithelial linings. The mucus layer is two layered; closest to the epithelial cell surface is a firmly adherent mucus layer and on top of that, a loosely transient adherent mucus layer. Both layers vary in thicknesses, ranging from 16-29 µm for the firmly adherent layer throughout the small intestine, whereas the loosely adherent layer is reported to have a thickness of varying from 123-480 µm in the small intestine (Ensign et al., 2012) . The main role of the mucus layer is to protect and lubricate the epithelial lining, and for drugs, the mucus layer may be a physical barrier to absorption. The mucus has variable turnover time in the GI tract, and the turnover time in the intestine is reported not to be longer than 2 h (Crater and Carrier, 2010; Ensign et al., 2012; C.-M. Lehr et al., 1991; Lehr, 2000) . For being able to study the interaction of the drug delivery system with the intestinal membrane and also the mucus layer, in situ intestinal perfusion studies are ideal (Lennernas, 1998; Lennernäs, 2014; Lozoya-Agullo et al., 2015; Song et al., 2013) . The single-pass intestinal perfusion model and closed-loop rat perfusion are both equally useful for obtaining information about drug absorption and interaction between the intestinal membrane and a drug delivery system. However, the closed-loop model has the advantage of measuring the absorption across a large part of the small intestine (Doluisio et al., 1969; Lozoya-Agullo et al., 2015) . Absorption data from intestinal perfusion in rats are found to correlate well with human absorption data (Fagerholm et al., 1996; Lozoya-Agullo et al., 2015) . In the current study, the amorphous sodium salt of furosemide (ASSF) was utilised as a model drug. Furosemide is a class IV compound in BCS. Hence, it has a poor aqueous solubility and a low intestinal permeability. Furosemide is a weak acid with pK a values of 9.9 and 3.5 (Matsuda et al., 1990) , therefore it is possible to utilise the salt form of the drug. ASSF has previously been shown to significantly improve the solubility and dissolution rate of furosemide when compared to the drug in the commonly available crystalline acid form (Nielsen et al., 2013a) . The poor intestinal absorption of furosemide is not only influenced by a low solubility, but is further complicated by the occurrence of site-specific absorption, partly in the stomach, but especially in the upper part of the small intestine, leading to a considerable interand intra-individual variation in oral drug bioavailability (20-60%) (Granero et al., 2010; Iannuccelli et al., 2000) . The intestinal absorption of furosemide is reported to be highly influenced by the dosage form (Granero et al., 2010) , and therefore, there is a further need to improve furosemide absorption and specifically reduce the variation in bioavailability. This task could be accomplished through the use of an advanced drug delivery system such as microcontainers. A previous study showed that microwells fabricated with the biopolymer poly-L-lactic acid (PLLA), filled with ASSF, and coated with the pH-sensitive polymer Eudragit L100 made it possible to control the release of ASSF .
The aim of the current study was to evaluate microcontainers in vitro, in situ and in vivo as a potential oral drug delivery system for a poorly water-soluble drug ( Figure 2) . The release and absorption of ASSF confined in microcontainers were investigated using Caco-2 cells. Furthermore, intestinal perfusion studies in rats were carried out to explore any interaction between the microcontainers and the small intestinal mucus. Finally, the oral bioavailability of ASSF in rats was determined with and without confinement in microcontainers.
Figure 2: Schematic of the studies carried out. A) Microcontainers fabricated on silicon and filled with amorphous sodium salt of furosemide (ASSF) and coated with Eudragit L100 to be tested for in vitro release. B) After filling the microcontainers with ASSF the transport of ASSF through Caco -2 cells was studied. C) Showing the microcontainers fabricated on silicon with a fluorocarbon coating followed by ASSF confined in the microcontainers and coated with Eudragit L100. The microcontainers were afterwards in situ and in vivo tested in rats.
Materials and methods

Materials
Furosemide (>98% purity) was purchased from Fagron Nordic (Copenhagen, Denmark), while taurocholic acid sodium salt hydrate (sodium taurocholate), 2-(N-morpholino)ethane sulfonic acid (MES), bovine serum albumin (BSA) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Eudragit L100 was obtained from Evonik Industries (Darmstadt, Germany) and Hank's Balanced Salt Solution (HBSS) and sodium bicarbonate (7.5% w/v) solution were purchased from Life Technologies Europe (Naerum, Denmark). Phosphatidylcholine (Lipoid S PC, purity ≥ 98%) was acquired from Lipoid AG (Ludwigshafen, Germany). Sodium dihydrogen phosphate monohydrate, potassium dihydrogen phosphate and di-sodium hydrogen phosphate dehydrate were obtained from Scharlau (Sentmenat, Spain), whereas sodium azide, sodium chloride, and potassium dihydrogen phosphate were acquired from Merck (Darmstadt, Germany). Dulbecco's Modified Eagle's Medium (DMEM), 90 U/mL penicillin, 90 µg/mL streptomycin, non-essential amino acids, L-glutamine were sourced from Sigma-Aldrich Danmark A/S (Broendby, Denmark), while foetal bovine serum (FBS), was obtained from Gibco, Fisher Scientific (Slangerup, Denmark). Scintillation cocktail (Ultima Gold™) and 14 C-mannitol (58.8 mCi/mmol) were purchased from PerkinElmer Inc. (Boston, MA, USA). T-75 culture flasks and Transwell® permeable supports (filters) (in polycarbonate with a 0.4 µm pore size and with a diameter of 2.4 cm) were acquired from Corning Costar, Fisher Scientific (Slangerup, Denmark). Silicon wafers (4-in 100 n-type) were purchased from Okmetic (Vantaa, Finland). SU-8 2075 and SU-8 Developer were provided by Microresist Technology GmbH (Berlin, Germany). Chromium masks were designed using L-Edit ® from Tanner EDA (Monrovia, CA, USA) and supplied by Delta Mask B.V. (GJ Enschede, the Netherlands). Ketoprofen (Imalgene®) was obtained from Merial® laboratories (Barcelona, Spain) and Medetomidine hydrochloride (Domtor®) was from Esteve Veterinaria® (Barcelona, Spain). Deionised water was obtained from an SG Ultra Clear water system (SG Water USA, LLC, Nashua, NH, USA) and was freshly produced in all cases. All other chemicals used were of analytical grade.
Manufacturing of SU-8 microcontainers
The microcontainers were fabricated as described previously with two steps of photolithography employing the negative epoxy-based photoresist, SU-8 (Nielsen et al., 2014 (Nielsen et al., , 2012 Tao and Desai, 2007) . The microcontainers were fabricated on silicon wafers (Figure 2A and 2B) , and for the in situ and in vivo studies, the microcontainers were further fabricated on a fluorocarbon coating deposited on top of the supporting silicon wafer by plasma polymerisation ( Figure 2C ). This enabled dry removal of the fabricated SU-8 structures from the support substrate in order to obtain individual microcontainers (Keller et al., 2007) . The microcontainers had an inner diameter and height of 223±3 μm and 270±3 μm, respectively, resulting in a volume of 10.6±0.5 nL. For the in vitro studies the silicon wafers supporting the fabricated microcontainers were cut into chips of 12.8×12.8 mm 2 with arrays of 25×25 containers with a pitch of 450 μm being contained on each chip.
Preparation of ASSF
The preparation of ASSF was carried out as described previously (Nielsen et al., 2013a) . Briefly, water and ethanol (96%) were mixed in a ratio of 10:1 v/v, and crystalline furosemide was added at a concentration of 0.4 w/v%, together with 5 M NaOH in a molar ratio of 1:1 with furosemide. The solution was spray dried on a Büchi Mini Spray-Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain ASSF.
Filling of ASSF into the microcontainers
ASSF powder was manually distributed on the microcontainer chip. The excess drug in between the microcontainers was then removed with pressurised air, leaving ASSF-filled microcontainers. The chip with microcontainers was weighed before and after filling to determine the amount of drug filled into the microcontainers. This was determined to be 7.5±1.5 mg of ASSF per chip corresponding to 12.0±2.4 µg/container.
Spray coating of the drug-filled microcontainers with Eudragit L100
A spray coating system (ExactaCoat, Sono Tek, USA) equipped with an ultrasonic nozzle actuated at 120 kHz (Keller et al., 2013) was used to deposit Eudragit L100 (dissolved to a 2 wt% solution in isopropyl alcohol) on the cavity of the drug-filled microcontainers in a set-up similar as previously described . The generator power was set to 1.5 W, and the polymer solution was pumped through the nozzle at a flow rate of 100 µL/min. Nitrogen gas at a pressure of 10 mbar was used to direct the beam of droplets onto the microcontainers, and the distance between nozzle and substrate was 40 mm with the beam diameter on the substrate being approximately 4 mm. The lateral movements of the nozzle were controlled by an x-y stage and the nozzle path was defined in the equipment software. The nozzle was moved line-byline at a speed of 25 mm/s, and the coating was repeated 60 times to obtain a coating thickness in the µm range. The thickness of the layer was measured using a surface profilometer (KLA-Tencor Alpha-Step IQ, CA, USA).
Scanning electron microscopy
The morphology of the microcontainers (drug-filled microcontainers with and without coating) was examined using scanning electron microscopy (SEM). The investigations were carried out using a Nova 600 NanoSEM from FEI (Eindhoven, the Netherlands). Imaging was performed in low-vacuum mode at a pressure of 0.6 mbar and an operation voltage of 5 kV. Prior to examination, the samples were mounted onto metal stubs and were tilted by 15-30°.
Preparation of media
For the drug release from the coated microcontainers, a medium simulating the composition of the fasted gastric fluid followed by a medium simulating the conditions of the fasted intestinal fluids were employed. The medium simulating the fasted gastric fluid with a pH of 1.6 was prepared in accordance with Vertzoni et al. (Vertzoni et al., 2005) , whereas the medium simulating the fasted intestinal state (pH 6.5) was prepared as described previously (Nielsen et al., 2013a (Nielsen et al., , 2013b . For the cell transport studies, a simulated intestinal medium containing 5 mM bile salt and 1.25 mM phospholipid at pH 6.5 was employed as a transport medium. The medium was prepared in HBSS buffer pH 6.5, a stock solution of which was prepared by mixing HBSS together with 10 mM of MES buffer, 7.5% sodium bicarbonate and BSA, made to volume with water and pH adjusted to 6.5. For preparation of the simulated intestinal medium, an appropriate quantity of a stock solution of phosphatidylcholine in chloroform (100 mg/mL) was first evaporated under a steady stream of nitrogen in order to form a lipid film. The volume of a stock solution of sodium taurocholate hydrate (6 mg/mL) required to achieve a concentration of 5 mM bile salt was then added together with the stock solution of HBSS, pH 6.5. The medium was stirred at 37°C overnight, followed by adjustment to pH 6.5 and then to a final volume with buffer (Nielsen et al., 2013a; Patel et al., 2006) . The basolateral medium for the Caco-2 cell studies consisted of a HBSS buffer at pH 7.4 (prepared by mixing a stock solution of HBSS buffer with HEPES buffer, 7.5% sodium bicarbonate, and BSA). After solubilisation, pH was adjusted to pH 7.4 (Patel et al., 2006) .
Release of ASSF from microcontainers
The in vitro release of ASSF from the microcontainers was tested using a µ-Diss profiler (pION INC, Woburn, MA, USA) in a similar set-up as described earlier (Nielsen et al., , 2014 . Experiments were carried out at 37°C employing a stirring rate of 100 rpm. The path length of the in situ UV probes was 1 mm, and each channel of the profiler was calibrated with its own standard curve prior to the experiments. The microcontainers were filled with ASSF and coated with Eudragit L100 as described above. The chips with microcontainers were attached to cylindrical magnetic stirring bars (using carbon pads) placed in the bottom of sample vials, and covered with 10 mL of stimulated gastric medium pH 1.6 for 120 min followed by simulated intestinal medium at pH 6.5 for 180 min. The in situ UV probes situated in each sample vial scanned and detected the absorbance of released/dissolved ASSF for a total duration of 300 min. The experiment was performed in 5 replicates.
Transport studies with ASSF
The Caco-2 cell line (HTB-37) was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German Collection of Microorganisms and Cell Cultures) (DSMZ GmbH, Braunschweig, Germany) and used between passage numbers 2 and 8. The cells were cultured as described by Larsen et al. (Larsen et al., 2008) . Transport experiments were performed on polarised cells after 18-20 days in culture on permeable supports. Apical to basolateral transport of ASSF either applied as bulk powder or filled into microcontainers across the Caco-2 cell layer was investigated, using simulated intestinal medium pH 6.5 (see section: 'Preparation of media') as transport medium. Transepithelial electrical resistance (TEER) was measured at room temperature prior to each transport experiments in a tissue resistance measurement chamber (Endohm, World Precision Instruments, Berlin, Germany) combined with a voltohmmeter (EVOM, World Precision Instruments). TEER values were also measured after the ASSF experiments (at 120 min). The ASSF transport was determined over a 120 min time period with cell plates circulating at 95 rpm on a KS15 Edmund Bühler Compact Shaker (Holm and Halby, Broendby, Denmark) coupled with a thermostatic water bath kept at 37°C. The filter-grown cell cultures were initially washed with pre-heated (37°C) HBSS buffer; subsequently, the transport experiments were initiated. The transport of ASSF as bulk powder or filled into microcontainers was determined by applying the powder or microcontainer chips in custom-made baskets ( Figure 3 ) hanging above the cell layer, in a similar set-up as previously described by Sander et al. (Sander et al., 2013) . For the bulk ASSF, 6.5±1.5 mg was weighed and added to the baskets hanging above the cell layer. The drug-filled microcontainers (containing 7.5±1.5 mg of drug) were added to the baskets with the cavity of the microcontainers immersed in apical medium. The simulated medium at pH 6.5 was utilised as the apical medium and HBSS pH 7.4 as the basolateral medium in volumes of 2.5 and 1.5 mL, respectively. In each experiment, controls with either medium alone or empty basket plus medium were also employed. Samples of 100 µL were withdrawn from the basolateral compartment after 15, 30, 45, 60, 90, and 120 min and were replaced with pre-heated HBSS buffer at pH 7.4. The samples were diluted two-fold with acetonitrile and centrifuged at 15,000 rpm for 15 min, following supernatants were transferred to HPLC vials. Samples were kept at -20°C until HPLC-UV analysis. The transport studies were carried out in replicates of 10-19. After completion of the transport studies of ASSF, the viability of the cells was investigated using 14 Cmannitol and measuring the permeability. The cell cultures were washed twice with HBSS buffer and after leaving the cells for 10 min at room temperature, the TEER was measured. Subsequently, the permeability experiments with mannitol were initiated by adding 1 mL of simulated medium containing 17.5 µM 14 Cmannitol (1 µCi) to the apical compartment and 1.5 mL HBSS buffer pH 7.4 to the basolateral compartment. The cells were incubated at 37°C at a circulating speed of 95 rpm. Sample volumes of 100 µL were withdrawn from the basolateral compartment after 15, 30, 45, and 60 min, and after completion of the 14 Cmannitol transport study, apical samples (20 µL) were also withdrawn. The samples were transferred to scintillation vials to which 2 mL of scintillation cocktail was added and the content of 14 C-mannitol was determined using a Tri-Carb® 2910TR liquid scintillation analyser (PerkinElmer, Boston, MA, USA).
HPLC and data analysis for cell transport studies
The amount of ASSF in samples from the transport studies was quantified by HPLC-UV using the method previously described (Nielsen et al., 2013a) , with the exception that a Phenomenex Luna C18 column with the dimensions of 2.1 x 50 mm, 3.5 µm was used. For the data analysis, flux (F) [mol/cm 2 /s] for the ASSF and apparent permeability (P a pp ) [cm/s] for 14 Cmannitol across the Caco-2 cells were calculated at steady state rate of permeation according to Eqs. 1 and 2, respectively.
where dQ/dt [mol/s] is the rate of drug permeation, A [cm 2 ] is the area of the inserts (2.4 cm 2 ), and C 0 [mol/cm 3 ] is the initial donor concentration of 14 C-mannitol.
Closed-loop intestinal perfusion in rats
Animal protocol number 2015/VSC/PEA/00084 was utilised for these studies of the Ethical Committees of the University of Valencia and the Valencian Regional Government. Female Wistar rats (220-270 g) were anaesthetised by intraperitoneal (IP) injection using a mixture of ketoprofen and medetomidine hydrochloride in a concentration of 1.5 mL/kg and 0.5 mL/kg, respectively. The intestinal perfusion surgeries were performed in a similar set-up as described in the literature (Doluisio et al., 1969; Lozoya-Agullo et al., 2015) . Briefly, it consists of preparing the small intestine as a closed compartment. A midline abdominal incision following the linea alba was made, and the small intestine was exposed. The bile duct was ligated in order to avoid drug enterohepatic circulation and the presence of bile salts in lumen. Two incisions were created in the intestine, the first at the beginning of the duodenal segment, and the second at the end of the ileum segment, just before the cecum, and the entire small intestine was cannulated through these incisions. Care was taken to avoid disturbance of the intestinal blood supply. In order to remove all intestinal contents, the small intestine was thoroughly flushed with pre-warmed (37°C) physiologic solution consisting of NaCl aqueous solution (9g/L) containing Na 2 HPO 4 •2H 2 O and NaH 2 PO 4 •2H 2 O both in water, and pH adjusted to 6.9. The catheters were then connected to a glass syringe using a stopcock three-way valve, and the intestine was carefully placed back into the peritoneal cavity with covering the abdomen with cotton wool pads to prevent peritoneal liquid evaporation and heat loss. The samples tested were 10 mL of ASSF solution (10 mg/mL) in 100 mM phosphate buffer pH 6.5, and Eudragitcoated ASSF-filled microcontainers dosed directly to the intestinal tubing at the same time as dosing 10 mL of 100 mM phosphate buffer, pH 6.5. As a control, empty microcontainers were dosed together with 10 mL of phosphate buffer. For acquiring a sample, the luminal content was pushed out from one syringe to the other using the stopcock valves and a sample of 200 µL was taken out. This procedure was done alternatively from the proximal syringe to the distal one, assuring the mixing of the solution in the intestinal lumen. The samples were collected every 5 min for a period of 30 min. After 30 min, the solution was emptied from the intestine and the volume was measured and a heart puncture was performed to collect the blood from the rat. The blood (to obtain the plasma) and the perfusion samples were centrifuged at 2500 rpm for 10 min. Following the 30 min of perfusion studies, the intestine was taken out of the rat, and placed on microscope slides. A light microscope (Eclipse E800, Nikon Instruments Europe) and Nikon ACT-1 (version 2.70) was used as software for visualising the microcontainers on the intestinal membrane. Water flux throughout the experiment can be significant and was therefore accounted for. A method based on direct measurement of the remaining solution volume was employed to calculate the water reabsorption zero order constant (k 0 ). For each tested compound, the initial volume (V 0 ) was determined on groups of four rats, while the endpoint volume (V t ) was measured on every animal used. The drug concentration in the samples was corrected as:
where C t represents the concentration in the absence of water reabsorption at time t, and C e the experimental value. The absorption rate coefficients (k a ) of the compounds were determined by nonlinear regression analysis of the remaining concentrations in the intestinal lumen (C t ) vs. time:
These absorption rate coefficients were then transformed into permeability values using the relationship:
where R is the effective radius of the intestinal segment, calculated from the area/volume relationship where the volume and length were measured at each experiment (Lozoya-Agullo et al., 2015).
Oral bioavailability study in rats
All animal care and experimental studies were approved by the Animal Welfare Committee, appointed by the Danish Ministry of Justice, and were carried out in compliance with EC Directive 2010/63/EU, the Danish law regulating experiments on animals and NIH Guidelines for the Care and Use of Laboratory Animals. The experiments were performed under the following license: 2012-15-2934-00186 and the experimental animal work was performed at the Department of Experimental Medicine, University of Copenhagen, Denmark, which is accredited by the Association of Assessment and Accreditation of Laboratory Animal Care (AAALAC). Male Sprague-Dawley rats (314-342 g) were purchased from Taconic (Bomholt, Denmark) and acclimatised for a minimum of 7 days in groups of two on wooden bedding (Tapvei, Kortteinen, Finland) in plastic cages on standard feed (Altromin 1324, Altromin Spezialfutter, Lage, Germany). The rats had free access to fresh tap water (also during the experiments) in an air-conditioned building with controlled environmental parameters (humidity 40-60%, temperature 20±1°C, light from 6am-6pm). Before entry into the experiments, the animals were fasted for approximately 6 h and randomly assigned to receive one of the treatments. One day prior to the in vivo experiments, Eudragitcoated ASSF-filled microcontainers were filled into gelatine capsules, size 9 (Torpac, NJ, USA) with a drug dose corresponding to 4.5 mg ASSF (equal to approximately 15 mg/kg dosed to the rats). As a reference 4.5 mg ASSF was filled into the capsules and the capsules were coated with Eudragit L100. The microcontainers were filled into the capsules by manually gently scrapping the microcontainers of the fluorocarbon coated chips. The bottom of the capsules were placed in a stand and filled via a funnel. The capsules (one capsule per rat) were dosed with a dosing syringe (Torpac, NJ, USA) to the bottom of the oesophagus of the rat. Blood samples (200 µL) were taken from the tail vein by individual venipuncture and collected into EDTA coated tubes. Samples were collected at 10, 20, 30, 45 min, and 1, 2, 3, 5, 7, and 24 h after drug administration. Plasma was harvested immediately by centrifugation at 3600 g (12 min) and stored at -20°C until further analysis. The in vivo studies were performed in 5 and 6 replicates for the microcontainers and the ASSF powder, respectively.
Liquid chromatography-mass spectrometry (LC-MS) analysis
Plasma samples were processed using 30 µL of the plasma spiked with 300 µL of acetonitrile to precipitate proteins. The mixtures were centrifuged at 3600 g for 15 min at room temperature. After centrifugation, the produced supernatants were transferred to HPLC vials and analysed by LC-MS, using the method described previous (Nielsen et al., 2013a) .
Pharmacokinetic analyses
The pharmacokinetic parameters following oral administration of ASSF were obtained by noncompartmental analysis. The area under the curve (AUC) of the plasma concentration versus time curves was determined by the linear log trapezoidal method from time t = 0 min either to t = 180 min or to the last plasma concentration measured at t = 1440 min after dosing. AUC values were used to calculate the relative bioavailability. The maximum furosemide plasma concentration (C ma x ) and time to peak concentration (T ma x ) were determined from the individual plasma concentration versus time curves.
Statistics
The in vitro and in situ data are expressed as mean±standard deviation (SD), whereas the in vivo data are stated as mean±standard error of mean (SEM). Where appropriate, statistical analysis was carried out using Student t-tests using GraphPad Prism version 6.05. P-values below 5% (p < 0.05) were considered statistically significant.
Results and discussion
The use of advanced drug delivery systems for oral delivery may be necessary, especially when delivering BCS class II and IV drugs, but also if delivering peptides or proteins by the oral route (Twibanire and Grindley, 2014) . It is therefore important to initially investigate the in vitro and in situ properties of the delivery system, in particular with respect to the release of the drug from the system in simulated media. It is furthermore of importance to study the intestinal absorption of the drug prior to animal testing.
Drug-filled microcontainers
In Figure 1 , an empty microcontainer fabricated in SU-8 is shown. Following the fabrication, the SU-8 microcontainers were filled with ASSF ( Figure 4A ). For the in vitro release, in situ perfusion and bioavailability studies, the microcontainers were further spray coated with a lid of the pH-sensitive polymer Eudragit L100 ( Figure 4B ) in order to provide controlled release, and additionally to maximize drug retention within microcontainers until the absorptive environment of the small intestine was reached. The Eudragit layer was found to be 9.7±0.3 µm (n= 5±SD) thick, with consistent thickness over the entire chip area. Figure 4 : SEM images of a microcontainer A) filled with ASSF, and B) filled with ASSF and coated with Eudragit L100 in a thickness of 9.7±0.3 µm (measured using a surface profilometer).
Release of ASSF from coated microcontainers
In order to obtain the best in vitro-in vivo correlation, it is important to evaluate the release of drug from an oral delivery system in conditions simulating the GI tract as closely as possible (Kostewicz et al., 2014) . Therefore, the release of ASSF from the Eudragit-coated microcontainers was studied in simulated gastric and intestinal media over periods of 120 min and 180 min, respectively (corresponding to the average transit time for drug in vivo in the stomach and intestine). The aim was to have a controlled drug delivery system, which could prevent release in the gastric environment, but facilitate a fast release in the absorptive upper small intestinal region, in order to provide the opportunity for maximal oral drug bioavailability. In Figure 5 , it can be seen that no release was observed in the first 120 min (gastric medium, pH 1.6) and when the medium was changed to intestinal medium (pH 6.5), a rapid release of ASSF from the microcontainers accompanying dissolution was observed. Of the initially incorporated ASSF, 88.2±1.4% was released and dissolved within the 180 min period of exposure to the simulated intestinal medium. The rapid release of ASSF following the pH shift was expected given that Eudragit L100 is known to dissolve above pH 6. Also, ASSF has been shown to have a very high dissolution rate in simulated intestinal medium (Nielsen et al., 2013a) . The release data therefore show that the Eudragit coating is sufficiently thick to
A) B)
serve as an effective lid for the microcontainers, protecting the drug from being released at pH 1.6, but providing no hindrance to a fast drug release at pH 6.5. It was found that the microcontainers were not a significant hindrance for a fast release compared to unconfined ASSF (bulk). After 2 min of dissolution 94.4±4.6% of the ASSF in bulk form was dissolved, whereas 81.7±3.1% of ASSF confined in microcontainers was released and dissolved. At the endpoint of the experiment (after 180 min), 85.9±2.2% of ASSF was released from the microcontainers. A small but significant difference (p-value 0.0253) was noted in comparison to the ASSF in bulk form, where 94.0±5.1% of the drug was dissolved at 180 min. From previous studies, it is known that ASSF is physically stable at storage conditions for 291 days, but during dissolution and thereby also release from the microcontainers, ASSF converts to a trihydrate quickly upon wetting. This will be the case for both ASSF in powder bulk and for ASSF confined in microcontainers (Nielsen et al., 2013a (Nielsen et al., , 2013b . The in vitro release characteristics of ASSF from the microcontainers are encouraging in terms of developing the microcontainers as an oral drug delivery system, as most of the ASSF confined in the microcontainers was released quickly and the characteristics of the release curves were very similar over the whole time period to the curves from the dissolution of ASSF in bulk form. The drug can, with a combination of the microcontainer and the Eudragit layer, be protected inside the device through the harsh environment of the stomach and then a fast release in the upper part of the intestine was obtained.
Figure 5: Release-time profiles obtained from SU-8 microcontainers filled with ASSF and coated with Eudragit L100 in gastric medium pH 1.6 (from 0-120 min) and intestinal medium pH 6.5 (120-300 min). Data are presented as mean± SD (n=5).
Flux of furosemide across the Caco-2 monolayer
Furosemide is a known substrate of efflux transporters such as the P-glycoproteins, and there is also a significant paracellular contribution to the passive uptake of furosemide (Granero et al., 2010) . The weakly acidic properties of furosemide result in the permeability being highly variable with pH (Pade and Stavchansky, 1997) . Pade et al. presented values of apparent permeability (P a pp ) of 0.012x10 -5 cm/s at pH 7.2, whereas a P a pp value of 0.51x10 -5 cm/s was reported at pH 5.4 (Pade and Stavchansky, 1997) . The P a pp values for furosemide in the literature is highly variable and values as low as 0.029x10 -5 cm/s (at pH 6.5) have been reported (Hilgendorf et al., 2000) . In Figure 6 , no apparent lag-time for the permeation of furosemide in bulk or in microcontainers was observed across the monolayer of Caco-2 cells. The flux of ASSF was calculated from the slope of the curves in the time interval of 15-120 min. At pH 6.5, the flux across the Caco-2 cell monolayer was calculated to be 1.13±0.95x10 -4 and 1.47±0.71x10 -4 µmol/cm 2 /s, for ASSF in bulk and microcontainers, respectively. There was no significant difference in the flux of bulk and confined ASSF (p-value 0.2569). When developing the microcontainers as an oral drug delivery system, it is a positive indication that there is no difference in the transport characteristics of the drug when dosed as bulk or confined in microcontainers. The Caco-2 cell culture model is well developed and absorption through the cell monolayer is found to be a key parameter in estimating the in vivo performance of a drug after oral administration (Amidon et al., 1995; Sjogren et al., 2013) . The in vitro-in vivo correlation seem to improve even further when the cell studies are performed in medium closely mimicking the properties of human intestinal fluid (as was done here) (Lind et al., 2007; Patel et al., 2006) . The viability of the cell layer after the 120 min of ASSF experiments was examined using a mannitol assay together with TEER values. The P a pp values for the mannitol can be found in the supplementary data (Table  A .1) where the controls refer to cell culture filters where no ASSF had been transported. There was a significant difference between the permeability of mannitol where bulk ASSF has been applied and the controls (p-value 0.0079), whereas no significant differences were observed between the mannitol permeability pre-treated with ASSF in microcontainers and the controls (p-value 0.1694), or the ASSF in microcontainers and bulk ASSF (p-value 0.1003). Furthermore, a drop in TEER values could be observed for the Caco-2 cells for all the treatments (supplementary data, Table A .1). It should however be noted that it has previously been reported that drops in TEER values can be observed when utilising a simulated intestinal medium (Ingels et al., 2002) . For the bio-relevance of the studies reported here, it was decided to utilise simulated intestinal medium even though it can cause a reduction in the integrity of the cell layer, as mimicking the conditions in the intestine is important when studying new formulation effects and delivery systems (Berginc et al., 2012; Patel et al., 2006) . In the present studies, the mannitol permeability was found to be a 100-fold higher compared to values reported in the literature (0.3-0.5 x 10 -6 cm/s) (Kumar et al., 2010) . It is speculated that furosemide may have a slightly toxic effect on the cells as the mannitol permeability is highest for the bulk ASSF (supplementary data, Table A .1) and the TEER values were also found lowest for this treatment -although this is not found reported in the literature.
In situ closed-loop rat intestinal perfusion
The in situ perfusion studies were essential to investigate if there was any interaction between intestine/intestinal mucus and the microcontainers. Earlier, intestinal perfusion studies have been used to investigate absorption mechanisms e.g. for drug suspensions (Xu et al., 2014) , and they are in general appropriate models for observing mechanisms of absorption and interactions. Furthermore, good in vitroin vivo correlation has been found between perfusion and oral absorption data in rats and thereby it has been concluded that in situ intestinal perfusion is useful in predicting in vivo pharmacokinetic characteristics in rats (Xu et al., 2014) . It was observed that after 30 min, the microcontainers were engulfed by the intestinal mucus when visualising the intestine and microcontainers under a light microscope (Figure 7) . In Figure 7A -D, empty microcontainers are visualised and it can be seen that both the empty and the coated microcontainers interacted with the intestinal mucus; the microcontainers were completely covered by the intestinal mucus. The intestinal mucus acts as a steric and interaction barrier (Nordgård et al., 2014) , and it seems as mucus was entangling the microcontainers and the drug is then released from the microcontainers before the microcontainers can be cleared away. To protect the mucosal epithelium the constant fast turnover of the mucus layer serves to remove potentially damaging compounds introduced to the GI tract, and therefore the microcontainers provide a transient mucoadhesion and thereby prolong the contact time for epithelial uptake of furosemide. However, furosemide was released within minutes from the microcontainers ( Figure 5 ) (Ensign et al., 2012; C. M. Lehr et al., 1991) , and this is probably why there was an increased absorption of furosemide through the intestinal wall. For investigations into the effect of interactions of the microcontainers with the intestinal mucus for the absorption of furosemide, the absorption rate constants were calculated for ASSF in microcontainers coated with Eudragit L100 and for ASSF in solution. The absorption rate constant for the ASSF confined in the microcontainers was calculated to be 1.91±0.22 h -1 , whereas the value was 1.23±0.47 h -1 for the solution, creating a significant difference (p-value: 0.0249) between the two groups tested (Figure 8 ). This correlates well with the observation that the microcontainers interact with and adhere to the intestinal wall, thereby increasing the absorption rate of ASSF. When dosing the solution of furosemide, the furosemide is likely to be quickly flushed further down in the intestine (where absorption is not occurring) due to the continuing flow of fluid through the small intestine (Sjögren et al., 2014) . It has earlier been reported that, unlike microparticles that experience a high intestinal and peristaltic shear, planar microdevices experience a low shear stress and remain in the upper intestine for a longer time (Hariharasudhan D. . Even though the microdevices described in the literature had other dimensions (200 µm in diameter and 4 µm in depth) than the microcontainers described here, it can be speculated that it is the same phenomenon that is observed also for non-planar devices as utilised in this study (Hariharasudhan D. . This leads to the argument that microcontainers could be a promising oral drug delivery system also for other types of drugs than poorly soluble drugs, e.g. for peptides, proteins and low permeable drugs. Furosemide is a loop diuretic and widely used orally for hypertension and oedema (Goud et al., 2011; Matsuda et al., 1990) , and therefore a rapid absorption will often be beneficial for the patients, but in case of other drug candidates where a prolonged release may be required other polymers than Eudragit L100 can be utilised as coating agents. 
Oral bioavailability in rats
To investigating the potential of microcontainers as an oral drug delivery system further, it was studied how the microcontainers would influence the oral bioavailability of ASSF. The mean plasma concentration versus time profiles of ASSF in microcontainers and ASSF in Eudragit-coated capsules are presented in Figure 9 , and the non-compartmental pharmacokinetic parameters are provided in Table 1 . For the first 180 min, no significant difference was observed for the AUC between ASSF confined in Eudragit-coated microcontainers and ASSF in capsules coated with Eudragit L100 (p-value: 0.8599). Additionally, no significant difference was observed between the two groups in terms of T ma x and C max (p-values of 0.310 and 0.8199, respectively). After 180 min however, a prolonged absorption for ASSF from microcontainers was seen, and this difference continued for the 1440 min the studies were carried out for ( Figure 9 and Table 1 ). This is reflected in a significant difference in the AUC 0-1440mi n between the two test groups (p-value: 0.0020), which resulted in a relative oral bioavailability of ASSF from the microcontainers of 220.2±43.2 % compared to the capsules. This correlates well with the in situ studies where the microcontainers were adhering to the mucus and releasing the ASSF in a prolonged fashion compared to the powder in the capsules. These results suggest that by the use of microcontainers, absorption of drugs can be prolonged and the bioavailability can be increased. Figure 9 : Plasma furosemide concentrations after dosing to rats of i) microcontainers filled with ASSF, coated with Eudragit L100 and filled into gelatin capsules and ii) ASSF powder in capsules with Eudragit coating. The data is presented as mean±SEM with n=6 for microcontainers and n=5 for capsules. Relative bioavailability was determined as: 100x(AUC mc /dose mc )/(AUC eudra gi t /dose eudra gi t ) * Significant difference (p-value: 0.0020)
Conclusion
Microcontainers fabricated in the polymer SU-8 were evaluated in vitro, in situ and in vivo for their properties as advanced oral drug delivery systems for poorly soluble drugs, using furosemide as a model drug. When filling the microcontainers with ASSF, it was found that drug release could be controlled by coating the cavity of the microcontainers with Eudragit L100 as no release was measured in simulated gastric medium, whereas rapid release in the simulated intestinal medium was observed. Furthermore, no significant difference was seen for the transport and flux of ASSF in Caco-2 cells, neither in the bulk form nor in the microcontainers. The in situ perfusion studies showed that the microcontainers were engulfed by the intestinal mucus resulting in an increased absorption rate for the confined ASSF compared to furosemide solution. In the oral bioavailability study in rats, differences of AUC were observed from 180 to 1440 min leading to a relative bioavailability of 220% of the ASSF in microcontainers compared to ASSF in capsules. These results indicate that it is possible to utilise the microcontainers as an oral drug delivery system, here shown for a poorly soluble model drug, but with perspective of serving as an oral drug delivery system for other drugs as well.
